Drug intelligence / Profile preview

cardiomyopeptidin

Development stage: Phase 4
Lead developer: Dalian Zhen-Ao Bio-Tech
Modality: Peptides
Administration: Intravenous

Overview

Cardiomyopeptidin is a peptide active substance extracted from the ventricular myocytes of healthy young pigs. It is being investigated for its cardioprotective effects, aiming to reduce infarct size, preserve viable myocardium, and improve microcirculation following myocardial injury, particularly in patients with acute ST-segment elevation myocardial infarction. It is also being explored for its cardioprotective effect in ICU patients with non-organic heart disease.

Other names: Cardiopeptidin

Beyond the preview

Go deeper on cardiomyopeptidin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cardiomyopeptidin.

Explore the full profile